1st Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$180,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 878 (115th), S. 204 (115th), H.R. 2368 (115th)

Taxation/Internal Revenue Code TAX

Orphan drug tax credit HR 1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (Tax Cuts and Jobs Act)

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (115th)

Medicare/Medicaid MMM

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Bipartisan Budget Act - HR 1892 - Medicare Part D

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (115th), H.R. 1892 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.